Search Results - "Romero Otero, Jose María"

Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data by Balaguer Germán, Jorge, Cortés García, Marcelino, Rodríguez López, Carlos, Romero Otero, Jose María, Esteban Chapel, Jose Antonio, Bollas Becerra, Antonio José, Nieto Roca, Luis, Taibo Urquía, Mikel, Pello Lázaro, Ana María, Tuñón Fernández, José

“…(1) Background: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in…”
Get full text

Use and Benefit of Sacubitril/Valsartan in Elderly Patients with Heart Failure with Reduced Ejection Fraction by Roca, Luis Nieto, García, Marcelino Cortés, Germán, Jorge Balaguer, Becerra, Antonio José Bollas, Otero, José María Romero, Chapel, José Antonio Esteban, López, Carlos Rodríguez, Lázaro, Ana María Pello, Urquía, Mikel Taibo, Tuñón, José

“…Heart failure (HF) is a highly prevalent syndrome in elderly subjects. Currently, multiple drugs have shown clinical benefits in patients with HF and reduced…”
Get full text

Abstract 4125999: Elderly patients with HF with reduced ejection fraction and renal failure: are SGLT2i a good option? by Balaguer German, jorge, CORTES GARCIA, MARCELINO, Rodriguez Lopez, Carlos, Romero Otero, Jose Maria, Esteban Chapel, Jose Antonio, Nieto Roca, Luis, Taibo Urquia, Mikel, Pello Lazaro, Ana Maria, Tunon, Jose

“…Abstract only SGLT-2 receptor inhibitors (SGLT-2i) have been shown to reduce cardiovascular mortality and hospitalisations for heart failure (HF) in patients…”
Get full text

Abstract 4126262: The impact of angiotensin receptor neprilysin inhibitors on the elderly population with heart failure and reduced ejection fraction: data from the real world by Balaguer German, jorge, CORTES GARCIA, MARCELINO, Rodriguez Lopez, Carlos, Romero Otero, Jose Maria, Esteban Chapel, Jose Antonio, Nieto Roca, Luis, Taibo Urquia, Mikel, Pello Lazaro, Ana Maria, Tunon, Jose

“…Abstract only Heart failure (HF) remains a disease of increasing prevalence and morbidity. Validation of new lines of therapy in the elderly are required due…”
Get full text